JW Lifescience Corporation (KRX:234080)

Market Cap	181.63B
Revenue (ttm)	243.64B
Net Income (ttm)	49.48B
Shares Out	15.48M
EPS (ttm)	3,195.76
PE Ratio	3.67
Forward PE	n/a
Dividend	500.00 (4.26%)
Ex-Dividend Date	Dec 27, 2024

Volume	10,360
Average Volume	32,903
Open	11,500
Previous Close	11,500
Day's Range	11,450 - 11,540
52-Week Range	10,000 - 12,930
Beta	0.41
RSI	46.52
Earnings Date	Aug 14, 2025

About JW Lifescience

JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 297
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 234080

Financial Performance

In 2024, JW Lifescience's revenue was 222.48 billion, an increase of 7.55% compared to the previous year's 206.86 billion. Earnings were 43.99 billion, an increase of 56.29%.